Cannabinoid Encyclopedia

Focused research review

What does research say about CBG, appetite, and metabolism?

CBG is being studied in animal feeding and metabolic models, with very little human evidence. It is too early to call it a reliable appetite or metabolic intervention.

Updated July 2026 18 research sources Human and early research

The short answer

What is the bottom line?

CBG has no established human result for appetite, weight, or metabolic health. 1 2 3

The approved literature includes rodent feeding, appetite, cachexia, and metabolic studies, plus limited human survey information. Animal feeding results and product-use surveys cannot establish that CBG will reliably change appetite, weight, glucose, or metabolism in people. 1 2 3

What this means: Appetite, body weight, blood markers, and metabolic disease are separate outcomes. A result in a pre-satiated rat or a survey response should not be treated as a general human metabolic recommendation. 1 2 3

How to read this answer: Appetite, body weight, blood markers, and metabolic disease are separate outcomes. A result in a pre-satiated rat or a survey response should not be treated as a general human metabolic recommendation. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBG, appetite, and metabolism.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Most CBG appetite and metabolic findings come from animal models, not controlled human studies. 1

  2. 2

    Appetite, weight, cachexia, glucose, insulin, and metabolic markers are different outcomes. 2

  3. 3

    The current evidence does not establish that CBG reliably changes appetite or metabolic health in people. 3

Choose your question

Which appetite or metabolic question matters to you?

Feeding, weight, cachexia, glucose, and metabolic markers are different research outcomes. Start with the one a study actually measured.

  1. 01Reader question

    Does CBG affect appetite?

    See the animal feeding context and why it does not establish a human result.

    Explore the evidence
  2. 02Reader question

    What about weight or blood sugar?

    Compare the separate metabolic questions represented in the source set.

    Explore the evidence
  3. 03Reader question

    What human evidence exists?

    See the limited human sources and their product-specific limits.

    Explore the evidence

Research areas

What researchers studied about CBG, appetite, and metabolism

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly preclinical

Appetite and metabolic outcomes

This part of the literature focuses on Appetite and metabolic outcomes. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

6 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

5 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

7 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CBG, appetite, and metabolism is not one kind of study. This source set includes 9 animal studies, 5 narrative or expert reviews, and 2 clinical studies in people. 3

The recorded populations or models include people or patients (8 sources) and animal models (7 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is appetite-related, weight, glucose, or metabolic outcomes (18 sources). Closely related outcome names can still describe different measurements. 5

The CBG, appetite, and metabolism source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

clinical study in people

Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.

On this page, this source examines CBG and appetite and metabolic outcomes. 1

Study type
clinical study in people
Population or model
animal models
Outcome focus
appetite-related, weight, glucose, or metabolic outcomes
Evidence stage
preclinical research

animal study

A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats.

On this page, this source examines CBG and appetite and metabolic outcomes. 2

Study type
animal study
Population or model
animal models
Outcome focus
appetite-related, weight, glucose, or metabolic outcomes
Evidence stage
preclinical research

animal study

Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.

On this page, this source examines CBG and appetite and metabolic outcomes. 3

Study type
animal study
Population or model
people or patients
Outcome focus
appetite-related, weight, glucose, or metabolic outcomes
Evidence stage
preclinical research

narrative or expert review

Cannabigerol and cannabichromene in Cannabis sativa L.

On this page, this source examines CBG and appetite and metabolic outcomes. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
appetite-related, weight, glucose, or metabolic outcomes
Evidence stage
evidence still limited

narrative or expert review

It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.

On this page, this source examines CBG and appetite and metabolic outcomes. 5

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
appetite-related, weight, glucose, or metabolic outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBG, appetite, and metabolism should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Does CBG increase appetite?

Animal feeding studies provide an early research signal, but there is no established human result that CBG reliably increases appetite. 7

Does CBG affect weight or metabolism?

The current source set includes animal metabolic research and limited human survey information, not established human intervention evidence. 8

Why are appetite and metabolic outcomes separate?

Eating behavior, body weight, glucose, insulin, lipids, and disease outcomes can change independently, so a study must name the specific outcome it measured. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. clinical study in people; preclinical research PubMed 27503475 DOI 10.1007/s00213-016-4397-4
  2. 2
    A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. animal study; preclinical research PubMed 28125508 DOI 10.1097/fbp.0000000000000285
  3. 3
    Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. animal study; preclinical research PubMed 31035309 DOI 10.1002/jcsm.12426
  4. 4
    Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited PubMed 36654096 DOI 10.2478/acph-2021-0021
  5. 5
    It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited PubMed 32899626 DOI 10.3390/molecules25184036
  6. 6
    In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. animal study; mechanism-focused research PubMed 33230154 DOI 10.1038/s41598-020-77175-y
  7. 7
    Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. clinical study in people; human research PubMed 34569849 DOI 10.1089/can.2021.0058
  8. 8
    Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. human research PubMed 32795544 DOI 10.1016/j.cca.2020.08.014
  9. 9
    Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. narrative or expert review; evidence still limited PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
  10. 10
    Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. narrative or expert review; evidence still limited PubMed 36397993 DOI 10.1155/2022/3336516
  11. 11
    Phytocannabinoids as novel therapeutic agents in CNS disorders. narrative or expert review; evidence still limited PubMed 21924288 DOI 10.1016/j.pharmthera.2011.09.002
  12. 12
    Cannabigerol - A potent regulator of insulin sensitivity in rat's skeletal muscle via targeting the sphingolipid metabolism and PI3K/Akt/mTOR pathway? animal study; preclinical research PubMed 40482851 DOI 10.1016/j.biocel.2025.106819
See all 18 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited / 1 linked research note PubMed 32899626
  2. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. animal study; mechanism-focused research / 1 linked research note PubMed 33230154
  3. Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. narrative or expert review; evidence still limited / 1 linked research note PubMed 42105814
  4. Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. animal study; mechanism-focused research / 1 linked research note PubMed 37305529
  5. Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? animal study; mechanism-focused research / 1 linked research note PubMed 41056638
  6. Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited / 1 linked research note PubMed 36654096
  7. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. clinical study in people; preclinical research / 1 linked research note PubMed 27503475
  8. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. narrative or expert review; evidence still limited / 1 linked research note PubMed 36397993
  9. A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. animal study; preclinical research / 1 linked research note PubMed 28125508
  10. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. clinical study in people; human research / 1 linked research note PubMed 34569849
  11. Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. animal study; preclinical research / 1 linked research note PubMed 31035309
  12. Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus. animal study; mechanism-focused research / 1 linked research note PubMed 31941059
  13. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. human research / 1 linked research note PubMed 32795544
  14. Phytocannabinoids as novel therapeutic agents in CNS disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 21924288
  15. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. animal study; mechanism-focused research / 1 linked research note PubMed 22543671
  16. Ensiling conditions and changes of cannabinoid concentration in industrial hemp. preclinical research / 1 linked research note PubMed 39192735
  17. Cannabigerol-A useful agent restoring the muscular phospholipids milieu in obese and insulin-resistant Wistar rats? animal study; preclinical research / 1 linked research note PubMed 38919749
  18. Cannabigerol - A potent regulator of insulin sensitivity in rat's skeletal muscle via targeting the sphingolipid metabolism and PI3K/Akt/mTOR pathway? animal study; preclinical research / 1 linked research note PubMed 40482851